Literature DB >> 11571275

p38 MAPK regulates group IIa phospholipase A2 expression in interleukin-1beta -stimulated rat neonatal cardiomyocytes.

N Degousee1, E Stefanski, T F Lindsay, D A Ford, R Shahani, C A Andrews, D J Thuerauf, C C Glembotski, T J Nevalainen, J Tischfield, B B Rubin.   

Abstract

Group IIa phospholipase A(2) (GIIa PLA(2)) is released by some cells in response to interleukin-1beta. The purpose of this study was to determine whether interleukin-1beta would stimulate the synthesis and release of GIIa PLA(2) from cardiomyocytes, and to define the role of p38 MAPK and cytosolic PLA(2) in the regulation of this process. Whereas GIIa PLA(2) mRNA was not identified in untreated cells, exposure to interleukin-1beta resulted in the sustained expression of GIIa PLA(2) mRNA. Interleukin-1beta also stimulated a progressive increase in cellular and extracellular GIIa PLA(2) protein levels and increased extracellular PLA(2) activity 70-fold. In addition, interleukin-1beta stimulated the p38 MAPK-dependent activation of the downstream MAPK-activated protein kinase, MAPKAP-K2. Treatment with the p38 MAPK inhibitor, SB202190, decreased interleukin-1beta stimulated MAPKAP-K2 activity, GIIa PLA(2) mRNA expression, GIIa PLA(2) protein synthesis, and the release of extracellular PLA(2) activity. Infection with an adenovirus encoding a constitutively active form of MKK6, MKK6(Glu), which selectively phosphorylates p38 MAPK, induced cellular GIIa PLA(2) protein synthesis and the release of GIIa PLA(2) and increased extracellular PLA(2) activity 3-fold. In contrast, infection with an adenovirus encoding a phosphorylation-resistant MKK6, MKK6(A), did not result in GIIa PLA(2) protein synthesis or release by unstimulated cardiomyocytes. In addition, infection with an adenovirus encoding MKK6(A) abrogated GIIa PLA(2) protein synthesis and release by interleukin-1beta-stimulated cells. These results provide direct evidence that p38 MAPK activation was necessary for interleukin-1beta-induced synthesis and release of GIIa PLA(2) by cardiomyocytes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11571275     DOI: 10.1074/jbc.M101516200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Annexin A1 attenuates neuroinflammation through FPR2/p38/COX-2 pathway after intracerebral hemorrhage in male mice.

Authors:  Yan Ding; Jerry Flores; Damon Klebe; Peng Li; Devin W McBride; Jiping Tang; John H Zhang
Journal:  J Neurosci Res       Date:  2019-06-03       Impact factor: 4.164

2.  Effects of lysophospholipids on tumor microenvironment.

Authors:  Johannes Rolin; Azzam A Maghazachi
Journal:  Cancer Microenviron       Date:  2011-09-09

3.  Interleukin-1beta affects calcium signaling and in vitro cell migration of astrocyte progenitors.

Authors:  Katharine Striedinger; Eliana Scemes
Journal:  J Neuroimmunol       Date:  2008-05-06       Impact factor: 3.478

4.  High PLA2 level is correlated with glioblastoma progression via regulating DNA replication.

Authors:  Haiyun Zhang; Hanwei Zhao; Hongliang Wang; Zhongbo Yin; Kai Huang; Minhong Yu
Journal:  J Cell Mol Med       Date:  2022-02-15       Impact factor: 5.310

5.  Lack of group X secreted phospholipase A₂ increases survival following pandemic H1N1 influenza infection.

Authors:  Alyson A Kelvin; Norbert Degousee; David Banner; Eva Stefanski; Alberto J Leόn; Denis Angoulvant; Stéphane G Paquette; Stephen S H Huang; Ali Danesh; Clinton S Robbins; Hossein Noyan; Mansoor Husain; Gerard Lambeau; Michael Gelb; David J Kelvin; Barry B Rubin
Journal:  Virology       Date:  2014-02-25       Impact factor: 3.616

Review 6.  Neuroinflammation: An Integrating Overview of Reactive-Neuroimmune Cell Interactions in Health and Disease.

Authors:  Rodolfo Kölliker-Frers; Lucas Udovin; Matilde Otero-Losada; Tamara Kobiec; María Inés Herrera; Jorge Palacios; Gabriela Razzitte; Francisco Capani
Journal:  Mediators Inflamm       Date:  2021-05-31       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.